BOSTON, August 5, 2015 /PRNewswire/ --
Aurigene will be presenting data at the poster session for its proprietary RAR-related orphan receptor gamma (RORγ) small molecule inverse agonists program, which is currently in preclinical development, at the World Congress on Inflammation Annual Meeting (August 8-12, Boston, MA).
Aurigene expects to nominate a candidate and initiate IND enabling studies for the program by October 2015.
Additional information on the presentations can be found below and abstracts can be accessed at http://inflammation2015.org/
Abstract Title: Discovery of Selective RORγ Inverse Agonists and Demonstration of Efficacy in Inflammatory Disease Models
Poster Category: Small Molecule Therapeutics for Inflammatory Diseases
Location: Exhibit Hall
Poster Board Number: B313
Date of Presentation: Sunday, August 9
Start Time: 4:30 PM EDT
End Time: 6:00 PM EDT
Aurigene is a specialized, discovery stage biotechnology company, developing novel and best-in-class therapies to treat cancer and inflammatory diseases. Aurigene's Programmed Death pathway program is the first of several immune checkpoint programs that are at different stages of discovery and preclinical development. Aurigene has partnered with several large and mid-pharma companies in the United States and Europe and has delivered multiple clinical compounds through these partnerships. With over 500 scientists, Aurigene has collaborated with 6 of the top 10 pharma companies. For more information, please visit Aurigene's website at http://aurigene.com/.
Director Strategic Alliances
SOURCE Aurigene Discovery